Hikal Q1: Loss Narrows, Margins Expand

📊 Q1 FY26 Results Snapshot Net Loss: ₹74M vs ₹224M (YoY) ⬇️ Revenue: ₹4B vs ₹3.8B (YoY) ⬆️ 5% EBITDA: ₹370M vs ₹251M (YoY) ⬆️ 47% EBITDA Margin: 9.2% vs 6.6% (YoY) ⬆️ 2.6 pp 📌 Fundamentals & Ratios (FY25 Snapshot) Revenue: ~₹15.5B Net Loss: ~₹0.6B (FY25) Debt-to-Equity: ~0.7 (moderate leverage) P/E Ratio: Negative (loss-making) ROE: Negative (losses weigh on returns) Dividend Yield: Nil (no payouts due to losses) 🏦 Business Drivers & Projects Pharma APIs: Growth in active pharmaceutical ingredients. Crop Protection Chemicals: Expanding agrochemicals portfolio. Contract Manufacturing: Partnerships with global pharma companies. Innovation Projects: Focus on R&D for specialty chemicals. Sustainability Initiatives: Green chemistry and eco-friendly production. ⚠️ Risks & Watchpoints Persistent Losses: Despite narrowing, company remains loss-making. Debt Levels: Moderate leverage could pressure balance sheet. Regulatory Risks: Pharma and agrochemical sectors face compliance challenges. Margin Sustainability: Expansion must be sustained across quarters. Global Competition: Intense rivalry in APIs and chemicals. 📑 Social Media–Ready Post 📌 Hikal Q1 FY26 Results Net Loss: ₹74M vs ₹224M (YoY) ⬇️ Revenue: ₹4B vs ₹3.8B (YoY) ⬆️ EBITDA: ₹370M vs ₹251M (YoY) ⬆️ EBITDA Margin: 9.2% vs 6.6% (YoY) ⬆️ 📊 Fundamentals & Ratios Revenue: ~₹15.5B Net Loss: ~₹0.6B Debt-to-Equity: ~0.7 P/E Ratio: Negative ROE: Negative Dividend Yield: Nil 🏦 Projects Pharma API growth Agrochemicals expansion Contract manufacturing partnerships Specialty chemical R&D Sustainability initiatives ⚠️ Risks Persistent losses Debt pressure Regulatory challenges Margin sustainability Global competition